Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation
Why the study?
Does catheter cryoballoon ablation reduce atrial fibrillation recurrence in patients receiving initial treatment for symptomatic, paroxysmal atrial fibrillation?
Key Points
- To compare catheter cryoballoon ablation with antiarrhythmic drug therapy as an initial treatment strategy for preventing arrhythmia recurrence in symptomatic, paroxysmal atrial fibrillation.
- Interventional randomized trial (EARLY-AF, NCT02825979) evaluating initial therapy for symptomatic, paroxysmal atrial fibrillation.
- Assigned patients to catheter cryoballoon ablation or antiarrhythmic drug therapy.
- Monitored atrial fibrillation recurrence via continuous cardiac rhythm monitoring.
- Catheter cryoballoon ablation produced a significantly lower rate of atrial fibrillation recurrence compared with antiarrhythmic drug therapy.
Structured PICO
Does catheter cryoballoon ablation reduce atrial fibrillation recurrence in patients receiving initial treatment for symptomatic, paroxysmal atrial fibrillation?
P
Population
Patients receiving initial treatment for symptomatic, paroxysmal atrial fibrillation
I
Intervention
Catheter cryoballoon ablation
C
Comparator
Antiarrhythmic drug therapy
O
Outcome
Atrial fibrillation recurrence as assessed by continuous cardiac rhythm monitoring
Catheter cryoballoon ablation is more effective than antiarrhythmic drug therapy for preventing atrial fibrillation recurrence as an initial treatment strategy for symptomatic, paroxysmal atrial fibrillation.
Discussion
No takes yet. Share an insight, caveat, or question.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The major takeaway is that for every arrhythmia outcome we studied, ablation was significantly better than antiarrhythmic drugs.”
CMChristine M. AlbertCardiologist, Cedars-Sinai Medical Center
“There's a lot of potentially asymptomatic AF that is going on in these patients, another reason why we don't stop anti[coagulation].”
“In the short term, this may be reflected as less recurrences of arrhythmia, improved quality of life, and less healthcare utilization. In the long run, this may translate into reduced disease progression, with subsequent reduction in the risk of stroke, heart failure and premature mortality. For the first time, these results clearly demonstrate that as an initial approach to Afib therapy, a Medtronic cryoablation is disease modifying and significantly lowers the progression of AFib.”
Implication
Supports cryoballoon ablation as initial therapy for symptomatic paroxysmal AF; confirms superiority over drugs in reducing recurrence.
Cite This Study
Andrade et al. (2020) studied this question.